$FBIO
Fortress Biotech, Inc.

2024 Q3 Form 10-Q Financial Statement

#000155837024015740 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q3
Revenue $14.63M
YoY Change -57.9%
Cost Of Revenue $5.285M
YoY Change -17.79%
Gross Profit $9.344M
YoY Change -67.01%
Gross Profit Margin 63.87%
Selling, General & Admin $21.99M
YoY Change 1.2%
% of Gross Profit 235.37%
Research & Development $9.446M
YoY Change -53.58%
% of Gross Profit 101.09%
Depreciation & Amortization $100.0K
YoY Change -75.0%
% of Gross Profit 1.07%
Operating Expenses $31.44M
YoY Change -25.29%
Operating Profit -$22.10M
YoY Change 60.6%
Interest Expense -$5.601M
YoY Change 181.46%
% of Operating Profit
Other Income/Expense, Net -$4.530M
YoY Change -242.68%
Pretax Income -$26.63M
YoY Change 151.58%
Income Tax $100.0K
% Of Pretax Income
Net Earnings -$12.87M
YoY Change 155.04%
Net Earnings / Revenue -87.96%
Basic Earnings Per Share -$0.76
Diluted Earnings Per Share -$0.76
COMMON SHARES
Basic Shares Outstanding 19.70M
Diluted Shares Outstanding 19.70M

Balance Sheet

Concept 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $58.85M
YoY Change -18.6%
Cash & Equivalents $58.85M
Short-Term Investments
Other Short-Term Assets $4.792M
YoY Change -23.94%
Inventory $11.79M
Prepaid Expenses
Receivables $10.67M
Other Receivables $174.0K
Total Short-Term Assets $86.28M
YoY Change -11.8%
LONG-TERM ASSETS
Property, Plant & Equipment $3.403M
YoY Change -50.35%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.345M
YoY Change -30.63%
Total Long-Term Assets $40.81M
YoY Change -22.6%
TOTAL ASSETS
Total Short-Term Assets $86.28M
Total Long-Term Assets $40.81M
Total Assets $127.1M
YoY Change -15.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $34.03M
YoY Change -23.92%
Accrued Expenses $64.50M
YoY Change -20.77%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $1.250M
YoY Change -58.33%
Total Short-Term Liabilities $70.31M
YoY Change -27.78%
LONG-TERM LIABILITIES
Long-Term Debt $52.47M
YoY Change 14.57%
Other Long-Term Liabilities $1.753M
YoY Change 2.75%
Total Long-Term Liabilities $1.753M
YoY Change 2.75%
TOTAL LIABILITIES
Total Short-Term Liabilities $70.31M
Total Long-Term Liabilities $1.753M
Total Liabilities $139.8M
YoY Change -14.63%
SHAREHOLDERS EQUITY
Retained Earnings -$734.1M
YoY Change 7.08%
Common Stock $28.00K
YoY Change 211.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $21.16M
YoY Change
Total Liabilities & Shareholders Equity $127.1M
YoY Change -15.59%

Cashflow Statement

Concept 2024 Q3
OPERATING ACTIVITIES
Net Income -$12.87M
YoY Change 155.04%
Depreciation, Depletion And Amortization $100.0K
YoY Change -75.0%
Cash From Operating Activities -$20.06M
YoY Change 19.54%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.711M
YoY Change -200.78%
NET CHANGE
Cash From Operating Activities -20.06M
Cash From Investing Activities 0.000
Cash From Financing Activities 2.711M
Net Change In Cash -17.35M
YoY Change 19.89%
FREE CASH FLOW
Cash From Operating Activities -$20.06M
Capital Expenditures $0.00
Free Cash Flow -$20.06M
YoY Change 19.47%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19697290
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7498653
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19041590
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7231004
dei Entity Central Index Key
EntityCentralIndexKey
0001429260
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
3427138
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
3427138
dei Entity Registrant Name
EntityRegistrantName
Fortress Biotech, Inc.
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27584600
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15093053
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.76
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.94
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.43
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.94
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35366
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-5157386
dei Entity Address Address Line1
EntityAddressAddressLine1
1111 Kane Concourse Suite 301
dei Entity Address City Or Town
EntityAddressCityOrTown
Bay Harbor Islands
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33154
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
652-4500
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58853000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
80927000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10671000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15222000
CY2024Q3 us-gaap Inventory Net
InventoryNet
11788000
CY2023Q4 us-gaap Inventory Net
InventoryNet
10206000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2583000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10500000
CY2024Q3 fbio Assets Held For Sale
AssetsHeldForSale
2209000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
86278000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
117022000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3403000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6505000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
14152000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
16990000
CY2024Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
2063000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
2438000
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
17844000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
20287000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3345000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4284000
CY2024Q3 us-gaap Assets
Assets
127085000
CY2023Q4 us-gaap Assets
Assets
167526000
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
64499000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
73562000
CY2024Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
850000
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
843000
CY2024Q3 fbio Warrant Liabilities Current
WarrantLiabilitiesCurrent
154000
CY2023Q4 fbio Warrant Liabilities Current
WarrantLiabilitiesCurrent
886000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2514000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2523000
CY2024Q3 fbio Convertible Preferred Shares Current
ConvertiblePreferredSharesCurrent
0
CY2023Q4 fbio Convertible Preferred Shares Current
ConvertiblePreferredSharesCurrent
3931000
CY2024Q3 fbio Partner Company Installment Payments Licenses Current
PartnerCompanyInstallmentPaymentsLicensesCurrent
1250000
CY2023Q4 fbio Partner Company Installment Payments Licenses Current
PartnerCompanyInstallmentPaymentsLicensesCurrent
3000000
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1038000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
163000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
70305000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
84908000
CY2024Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
52473000
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
60856000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
15292000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18282000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1753000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1893000
CY2024Q3 us-gaap Liabilities
Liabilities
139823000
CY2023Q4 us-gaap Liabilities
Liabilities
165939000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2024Q3 fbio Preferred Stock Shares Designated
PreferredStockSharesDesignated
5000000
CY2023Q4 fbio Preferred Stock Shares Designated
PreferredStockSharesDesignated
5000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
3427138
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
3427138
CY2024Q3 us-gaap Preferred Stock Liquidation Preference
PreferredStockLiquidationPreference
25.00
CY2023Q4 us-gaap Preferred Stock Liquidation Preference
PreferredStockLiquidationPreference
25.00
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
3000
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
3000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27584600
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15093053
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
28000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
15000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
755229000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
717396000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-734102000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-694870000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
21158000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
22544000
CY2024Q3 us-gaap Minority Interest
MinorityInterest
-33896000
CY2023Q4 us-gaap Minority Interest
MinorityInterest
-20957000
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-12738000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1587000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
127085000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
167526000
CY2024Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
14629000
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
15279000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
42514000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
44405000
CY2023Q3 fbio Collaboration Revenue
CollaborationRevenue
182000
fbio Collaboration Revenue
CollaborationRevenue
546000
CY2023Q3 us-gaap Other Income
OtherIncome
19260000
us-gaap Other Income
OtherIncome
19519000
CY2024Q3 us-gaap Revenues
Revenues
14629000
CY2023Q3 us-gaap Revenues
Revenues
34752000
us-gaap Revenues
Revenues
42555000
us-gaap Revenues
Revenues
64567000
CY2024Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5285000
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6429000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
18642000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
20645000
CY2024Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
9446000
CY2023Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
20288000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
46941000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
87702000
CY2023Q3 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
60000
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
4293000
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
21993000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
21733000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
60867000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
71512000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
2649000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
3143000
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
36724000
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
48510000
us-gaap Costs And Expenses
CostsAndExpenses
129099000
us-gaap Costs And Expenses
CostsAndExpenses
187295000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-22095000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13758000
us-gaap Operating Income Loss
OperatingIncomeLoss
-86544000
us-gaap Operating Income Loss
OperatingIncomeLoss
-122728000
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
589000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
547000
us-gaap Investment Income Interest
InvestmentIncomeInterest
2157000
us-gaap Investment Income Interest
InvestmentIncomeInterest
2296000
CY2024Q3 fbio Interest Expense And Finance Fees
InterestExpenseAndFinanceFees
6209000
CY2023Q3 fbio Interest Expense And Finance Fees
InterestExpenseAndFinanceFees
2534000
fbio Interest Expense And Finance Fees
InterestExpenseAndFinanceFees
10933000
fbio Interest Expense And Finance Fees
InterestExpenseAndFinanceFees
13255000
CY2024Q3 fbio Gain Loss On Common Stock Warrant Liabilities
GainLossOnCommonStockWarrantLiabilities
19000
CY2023Q3 fbio Gain Loss On Common Stock Warrant Liabilities
GainLossOnCommonStockWarrantLiabilities
4542000
fbio Gain Loss On Common Stock Warrant Liabilities
GainLossOnCommonStockWarrantLiabilities
-578000
fbio Gain Loss On Common Stock Warrant Liabilities
GainLossOnCommonStockWarrantLiabilities
10708000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1071000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
620000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1334000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2049000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4530000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3175000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8020000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2300000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-26625000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10583000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-94564000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-125028000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
69000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
141000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-24000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
142000
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-26694000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-10724000
us-gaap Profit Loss
ProfitLoss
-94540000
us-gaap Profit Loss
ProfitLoss
-125170000
CY2024Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-13827000
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-5679000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-55308000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-73812000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-12867000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5045000
us-gaap Net Income Loss
NetIncomeLoss
-39232000
us-gaap Net Income Loss
NetIncomeLoss
-51358000
CY2024Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
2173000
CY2023Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
2008000
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
7006000
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
6024000
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15040000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7053000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-46238000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-57382000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.76
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.76
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.94
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.94
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.43
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.43
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.94
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.94
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19697290
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19697290
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7498653
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7498653
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19041590
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19041590
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7231004
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7231004
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-14598000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
6573000
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7360000
CY2024Q3 fbio Warrant Charge In Conjunction With Oaktree Debt
WarrantChargeInConjunctionWithOaktreeDebt
1314000
CY2024Q3 fbio Issuance Of Common Stock For At Market Offering
IssuanceOfCommonStockForAtMarketOffering
568000
CY2024Q3 fbio Partner Company Equity Offering
PartnerCompanyEquityOffering
10850000
CY2024Q3 fbio Adjustments To Additional Paid In Capital Subsidiary At Market Offering
AdjustmentsToAdditionalPaidInCapitalSubsidiaryAtMarketOffering
1878000
CY2024Q3 fbio Issuance Of Common Stock Under Partner Companys Employee Stock Purchase Program
IssuanceOfCommonStockUnderPartnerCompanysEmployeeStockPurchaseProgram
124000
CY2024Q3 fbio Adjustments To Additional Paid In Capital Dividends In Excess Of Common Stock
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfCommonStock
176000
CY2024Q3 fbio Partner Company Exercise Of Options For Cash
PartnerCompanyExerciseOfOptionsForCash
63000
CY2024Q3 us-gaap Net Income Loss Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
13827000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-12867000
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-12738000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-15943000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
4377000
CY2023Q3 fbio Issuance Of Common Stock For At Market Offering
IssuanceOfCommonStockForAtMarketOffering
837000
CY2023Q3 fbio Common Shares Issued For Dividend On Partner Company S Convertible Preferred Shares
CommonSharesIssuedForDividendOnPartnerCompanySConvertiblePreferredShares
68000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
2008000
CY2023Q3 fbio Partner Company Equity Offering
PartnerCompanyEquityOffering
9261000
CY2023Q3 fbio Adjustments To Additional Paid In Capital Subsidiary At Market Offering
AdjustmentsToAdditionalPaidInCapitalSubsidiaryAtMarketOffering
160000
CY2023Q3 fbio Issuance Of Common Stock Under Partner Companys Employee Stock Purchase Program
IssuanceOfCommonStockUnderPartnerCompanysEmployeeStockPurchaseProgram
90000
CY2023Q3 fbio Adjustments To Additional Paid In Capital Dividends In Excess Of Common Stock
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfCommonStock
185000
CY2023Q3 fbio Partner Company S Exercise Of Options For Cash
PartnerCompanySExerciseOfOptionsForCash
21000
CY2023Q3 us-gaap Noncontrolling Interest Increase From Sale Of Parent Equity Interest
NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
802000
CY2023Q3 us-gaap Net Income Loss Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
5679000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5045000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-13243000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1587000
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
16429000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
51000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
17478000
fbio Warrant Charge In Conjunction With Oaktree Debt
WarrantChargeInConjunctionWithOaktreeDebt
1313000
fbio Issuance Of Common Stock For At Market Offering
IssuanceOfCommonStockForAtMarketOffering
3394000
fbio Common Shares Issued For Dividend On Partner Company S Convertible Preferred Shares
CommonSharesIssuedForDividendOnPartnerCompanySConvertiblePreferredShares
114000
fbio Common Shares Issued For Exchange Of Partner Company S Convertible Preferred Shares
CommonSharesIssuedForExchangeOfPartnerCompanySConvertiblePreferredShares
3409000
fbio Warrants Issued In Conjunction With Exchange Of Partner Company S Convertible Preferred Shares
WarrantsIssuedInConjunctionWithExchangeOfPartnerCompanySConvertiblePreferredShares
341000
us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
4016000
fbio Partner Company Equity Offering
PartnerCompanyEquityOffering
28852000
fbio Adjustments To Additional Paid In Capital Subsidiary At Market Offering
AdjustmentsToAdditionalPaidInCapitalSubsidiaryAtMarketOffering
3657000
fbio Issuance Of Common Stock Under Partner Companys Employee Stock Purchase Program
IssuanceOfCommonStockUnderPartnerCompanysEmployeeStockPurchaseProgram
257000
fbio Adjustments To Additional Paid In Capital Dividends In Excess Of Common Stock
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfCommonStock
528000
fbio Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
30000
fbio Adjustments To Additional Paid In Capital Exercise Of Partner Company Options And Warrants
AdjustmentsToAdditionalPaidInCapitalExerciseOfPartnerCompanyOptionsAndWarrants
9434000
us-gaap Net Income Loss Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
55308000
us-gaap Net Income Loss
NetIncomeLoss
-39232000
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-12738000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
50025000
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
13325000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13155000
fbio Issuance Of Common Stock For At Market Offering
IssuanceOfCommonStockForAtMarketOffering
2005000
fbio Common Shares Issued For Dividend On Partner Company S Convertible Preferred Shares
CommonSharesIssuedForDividendOnPartnerCompanySConvertiblePreferredShares
199000
us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
6024000
fbio Partner Company Equity Offering
PartnerCompanyEquityOffering
31238000
fbio Adjustments To Additional Paid In Capital Subsidiary At Market Offering
AdjustmentsToAdditionalPaidInCapitalSubsidiaryAtMarketOffering
160000
fbio Partner Company S Exercise Of Options For Cash
PartnerCompanySExerciseOfOptionsForCash
24000
fbio Issuance Of Common Stock Under Partner Companys Employee Stock Purchase Program
IssuanceOfCommonStockUnderPartnerCompanysEmployeeStockPurchaseProgram
178000
fbio Adjustments To Additional Paid In Capital Dividends In Excess Of Common Stock
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfCommonStock
556000
fbio Adjustments To Additional Paid In Capital Stock Issued For Research And Development Expenses
AdjustmentsToAdditionalPaidInCapitalStockIssuedForResearchAndDevelopmentExpenses
1233000
fbio Stock Issued During Period Value Cash Less Exercise Of Warrants
StockIssuedDuringPeriodValueCashLessExerciseOfWarrants
272000
us-gaap Noncontrolling Interest Increase From Sale Of Parent Equity Interest
NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
6693000
us-gaap Net Income Loss Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
73812000
us-gaap Net Income Loss
NetIncomeLoss
-51358000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-13243000
us-gaap Profit Loss
ProfitLoss
-94540000
us-gaap Profit Loss
ProfitLoss
-125170000
us-gaap Depreciation
Depreciation
896000
us-gaap Depreciation
Depreciation
1853000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-29000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
1351000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
823000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
492000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1754000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2524000
fbio Accretion Of Partner Company Convertible Preferred Shares
AccretionOfPartnerCompanyConvertiblePreferredShares
-737000
fbio Accretion Of Partner Company Convertible Preferred Shares
AccretionOfPartnerCompanyConvertiblePreferredShares
687000
us-gaap Paid In Kind Interest
PaidInKindInterest
0
us-gaap Paid In Kind Interest
PaidInKindInterest
353000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2457000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2796000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2443000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2952000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2366000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1561000
us-gaap Share Based Compensation
ShareBasedCompensation
16429000
us-gaap Share Based Compensation
ShareBasedCompensation
13325000
fbio Issuance Of Common Stock For Research And Development Expenses
IssuanceOfCommonStockForResearchAndDevelopmentExpenses
0
fbio Issuance Of Common Stock For Research And Development Expenses
IssuanceOfCommonStockForResearchAndDevelopmentExpenses
1233000
fbio Common Shares Issued For Exchange Of Partner Company Convertible Preferred Shares
CommonSharesIssuedForExchangeOfPartnerCompanyConvertiblePreferredShares
114000
fbio Common Shares Issued For Exchange Of Partner Company Convertible Preferred Shares
CommonSharesIssuedForExchangeOfPartnerCompanyConvertiblePreferredShares
199000
fbio Change In Fair Value Of Contingently Issuable Warrants
ChangeInFairValueOfContingentlyIssuableWarrants
427000
fbio Change In Fair Value Of Contingently Issuable Warrants
ChangeInFairValueOfContingentlyIssuableWarrants
-10708000
fbio Research And Development Licenses Acquired Expense
ResearchAndDevelopmentLicensesAcquiredExpense
0
fbio Research And Development Licenses Acquired Expense
ResearchAndDevelopmentLicensesAcquiredExpense
3060000
fbio Deconsolidation And Dissolution Gain Loss Amount
DeconsolidationAndDissolutionGainLossAmount
0
fbio Deconsolidation And Dissolution Gain Loss Amount
DeconsolidationAndDissolutionGainLossAmount
-4127000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
2649000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
3143000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3728000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-19727000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1582000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-3135000
us-gaap Increase Decrease Due From Other Related Parties
IncreaseDecreaseDueFromOtherRelatedParties
7000
us-gaap Increase Decrease Due From Other Related Parties
IncreaseDecreaseDueFromOtherRelatedParties
27000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3903000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3217000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-939000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1107000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-7118000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-17018000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
7000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
84000
fbio Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-2999000
fbio Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-1739000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
735000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-638000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-67284000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-93290000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
0
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
3000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
35000
us-gaap Proceeds From Sale Of Other Property Plant And Equipment
ProceedsFromSaleOfOtherPropertyPlantAndEquipment
0
us-gaap Proceeds From Sale Of Other Property Plant And Equipment
ProceedsFromSaleOfOtherPropertyPlantAndEquipment
6000000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
0
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
5000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
5000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2040000
us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
4016000
us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
6024000
fbio Proceeds From Issuance Of Common Stock Excluding At Market Offerings
ProceedsFromIssuanceOfCommonStockExcludingAtMarketOfferings
17478000
fbio Proceeds From Issuance Of Common Stock Excluding At Market Offerings
ProceedsFromIssuanceOfCommonStockExcludingAtMarketOfferings
13248000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3394000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2056000
fbio Proceeds From Issuance Of Common Stock From Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockFromEmployeeStockPurchasePlan
51000
fbio Proceeds From Issuance Of Common Stock From Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockFromEmployeeStockPurchasePlan
0
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
30000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
fbio Proceeds From Subsidiary S Employee Stock Purchase Plan
ProceedsFromSubsidiarySEmployeeStockPurchasePlan
257000
fbio Proceeds From Subsidiary S Employee Stock Purchase Plan
ProceedsFromSubsidiarySEmployeeStockPurchasePlan
178000
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
528000
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
556000
fbio Proceeds From Partner Companies Sale Of Stock And Warrants Net
ProceedsFromPartnerCompaniesSaleOfStockAndWarrantsNet
37128000
fbio Proceeds From Partner Companies Sale Of Stock And Warrants Net
ProceedsFromPartnerCompaniesSaleOfStockAndWarrantsNet
33805000
fbio Proceeds From Issuance Of Subsidiaries At Market Offering
ProceedsFromIssuanceOfSubsidiariesAtMarketOffering
3657000
fbio Proceeds From Issuance Of Subsidiaries At Market Offering
ProceedsFromIssuanceOfSubsidiariesAtMarketOffering
160000
fbio Proceeds From Exercise Of Equity Grants
ProceedsFromExerciseOfEquityGrants
0
fbio Proceeds From Exercise Of Equity Grants
ProceedsFromExerciseOfEquityGrants
24000
fbio Payment Of Oaktree Note
PaymentOfOaktreeNote
51000000
fbio Payment Of Oaktree Note
PaymentOfOaktreeNote
0
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
625000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1000000
fbio Proceeds From Issuance Of Partner Company Convertible Preferred Shares
ProceedsFromIssuanceOfPartnerCompanyConvertiblePreferredShares
0
fbio Proceeds From Issuance Of Partner Company Convertible Preferred Shares
ProceedsFromIssuanceOfPartnerCompanyConvertiblePreferredShares
854000
fbio Proceeds From Stock And Warrants Issued For Exchange Of Partner Company Preferred Shares
ProceedsFromStockAndWarrantsIssuedForExchangeOfPartnerCompanyPreferredShares
341000
fbio Proceeds From Stock And Warrants Issued For Exchange Of Partner Company Preferred Shares
ProceedsFromStockAndWarrantsIssuedForExchangeOfPartnerCompanyPreferredShares
0
fbio Payment Of Debt Issuance Costs Associated With Partner Company Share Settled Notes
PaymentOfDebtIssuanceCostsAssociatedWithPartnerCompanyShareSettledNotes
0
fbio Payment Of Debt Issuance Costs Associated With Partner Company Share Settled Notes
PaymentOfDebtIssuanceCostsAssociatedWithPartnerCompanyShareSettledNotes
210000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
33718000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
4950000
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
-91000
us-gaap Repayments Of Debt
RepaymentsOfDebt
0
us-gaap Repayments Of Debt
RepaymentsOfDebt
50375000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
0
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
28000000
us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
0
us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
30948000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
44835000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-10879000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-22449000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-106209000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
83365000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
180954000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60916000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
74745000
us-gaap Interest Paid Net
InterestPaidNet
5401000
us-gaap Interest Paid Net
InterestPaidNet
6590000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
115000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-17000
fbio Exchange Of Partner Company Convertible Preferred Shares
ExchangeOfPartnerCompanyConvertiblePreferredShares
3408000
fbio Exchange Of Partner Company Convertible Preferred Shares
ExchangeOfPartnerCompanyConvertiblePreferredShares
0
fbio Fair Value Of Assets Received By Partner Company In Repurchase Transaction
FairValueOfAssetsReceivedByPartnerCompanyInRepurchaseTransaction
2209000
fbio Fair Value Of Assets Received By Partner Company In Repurchase Transaction
FairValueOfAssetsReceivedByPartnerCompanyInRepurchaseTransaction
0
fbio Fair Value Of Supplies Received By Partner Company Expensed To Research And Development
FairValueOfSuppliesReceivedByPartnerCompanyExpensedToResearchAndDevelopment
2509000
fbio Fair Value Of Supplies Received By Partner Company Expensed To Research And Development
FairValueOfSuppliesReceivedByPartnerCompanyExpensedToResearchAndDevelopment
0
fbio Partner Company Accounts Receivable Write Off Related To Repurchase Transaction
PartnerCompanyAccountsReceivableWriteOffRelatedToRepurchaseTransaction
-6967000
fbio Partner Company Accounts Receivable Write Off Related To Repurchase Transaction
PartnerCompanyAccountsReceivableWriteOffRelatedToRepurchaseTransaction
0
fbio Partner Company Accounts Payable Write Off Related To Repurchase Transaction
PartnerCompanyAccountsPayableWriteOffRelatedToRepurchaseTransaction
3644000
fbio Partner Company Accounts Payable Write Off Related To Repurchase Transaction
PartnerCompanyAccountsPayableWriteOffRelatedToRepurchaseTransaction
0
fbio Partner Company S Net Purchase Consideration Of Assets Recorded To Accrued Other
PartnerCompanySNetPurchaseConsiderationOfAssetsRecordedToAccruedOther
-1295000
fbio Partner Company S Net Purchase Consideration Of Assets Recorded To Accrued Other
PartnerCompanySNetPurchaseConsiderationOfAssetsRecordedToAccruedOther
0
fbio Unpaid Partner Company Offering Cost
UnpaidPartnerCompanyOfferingCost
0
fbio Unpaid Partner Company Offering Cost
UnpaidPartnerCompanyOfferingCost
575000
fbio Partner Company Derivative Warrant Liability Associated With Partner Company Share Settled Notes
PartnerCompanyDerivativeWarrantLiabilityAssociatedWithPartnerCompanyShareSettledNotes
0
fbio Partner Company Derivative Warrant Liability Associated With Partner Company Share Settled Notes
PartnerCompanyDerivativeWarrantLiabilityAssociatedWithPartnerCompanyShareSettledNotes
33000
fbio Warrants Issued1
WarrantsIssued1
1313000
fbio Warrants Issued1
WarrantsIssued1
0
CY2024Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
140000
CY2023Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
fbio Unpaid Public Offering Costs
UnpaidPublicOfferingCosts
0
fbio Unpaid Public Offering Costs
UnpaidPublicOfferingCosts
50000
fbio Prepaid Offering Costs
PrepaidOfferingCosts
0
fbio Prepaid Offering Costs
PrepaidOfferingCosts
94000
fbio Unpaid Research And Development License Acquired
UnpaidResearchAndDevelopmentLicenseAcquired
0
fbio Unpaid Research And Development License Acquired
UnpaidResearchAndDevelopmentLicenseAcquired
60000
fbio Number Of Partner Companies That Are Publicly Traded
NumberOfPartnerCompaniesThatArePubliclyTraded
4
fbio Number Of Partner Companies That Have Consummated Strategic Partnerships With Industry Leaders
NumberOfPartnerCompaniesThatHaveConsummatedStrategicPartnershipsWithIndustryLeaders
3
CY2024Q3 fbio Cash And Cash Equivalents Parent Company
CashAndCashEquivalentsParentCompany
25600000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. The Company’s significant estimates include, but are not limited to provisions for coupons, chargebacks, wholesaler fees, specialty pharmacy discounts, managed care rebates, product returns, inventory realization, valuation of intangible assets, useful lives assigned to long-lived assets and amortizable intangible assets, fair value of stock options and warrants, stock-based compensation, common stock issued to acquire licenses, accrued expenses and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.</p>
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58853000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
72307000
CY2024Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
2063000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
2438000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60916000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
74745000
CY2024Q3 fbio Assets Held For Sale
AssetsHeldForSale
2200000
CY2024Q2 fbio Number Of Days To Dispose Of Assets Purchased
NumberOfDaysToDisposeOfAssetsPurchased
P180D
CY2024Q3 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
3551000
CY2023Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
4640000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
884000
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
8718000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
4987000
CY2024Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
481000
CY2023Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
305000
CY2024Q3 us-gaap Inventory Net
InventoryNet
11788000
CY2023Q4 us-gaap Inventory Net
InventoryNet
10206000
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
15368000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
15397000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11965000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8892000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3403000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6505000
CY2024Q3 us-gaap Depreciation
Depreciation
100000
CY2023Q3 us-gaap Depreciation
Depreciation
400000
us-gaap Depreciation
Depreciation
900000
us-gaap Depreciation
Depreciation
1900000
us-gaap Impairment Of Leasehold
ImpairmentOfLeasehold
2200000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
400000
CY2023Q4 fbio Warrant Liabilities Current
WarrantLiabilitiesCurrent
886000
CY2024Q3 fbio Warrant Liabilities Current
WarrantLiabilitiesCurrent
154000
CY2024Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2877000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
4144000
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
52473000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
60856000
CY2024Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
2236000
CY2024Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
3973000
CY2024Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
6209000
CY2023Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1877000
CY2023Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
657000
CY2023Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
2534000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
34030000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
34810000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2344000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1681000
CY2024Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
6064000
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
8531000
CY2024Q3 fbio Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
7586000
CY2023Q4 fbio Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
11644000
CY2024Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
1601000
CY2023Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
2015000
CY2024Q3 fbio Accrued Coupon Expense Current
AccruedCouponExpenseCurrent
6321000
CY2023Q4 fbio Accrued Coupon Expense Current
AccruedCouponExpenseCurrent
9987000
CY2024Q3 fbio Accrued Return Reserve Current
AccruedReturnReserveCurrent
3430000
CY2023Q4 fbio Accrued Return Reserve Current
AccruedReturnReserveCurrent
4077000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3123000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
817000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
64499000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
73562000
CY2024Q3 fbio Effect Of Series Preferred Dividends On Net Loss Per Share Calculation
EffectOfSeriesPreferredDividendsOnNetLossPerShareCalculation
2000000.0
fbio Effect Of Series Preferred Dividends On Net Loss Per Share Calculation
EffectOfSeriesPreferredDividendsOnNetLossPerShareCalculation
6000000.0
CY2024Q3 fbio Effect Of Partner Company Deemed Dividends On Net Loss Per Share Calculation
EffectOfPartnerCompanyDeemedDividendsOnNetLossPerShareCalculation
200000
fbio Effect Of Partner Company Deemed Dividends On Net Loss Per Share Calculation
EffectOfPartnerCompanyDeemedDividendsOnNetLossPerShareCalculation
1000000.0
CY2023Q3 fbio Effect Of Series Preferred Dividends On Net Loss Per Share Calculation
EffectOfSeriesPreferredDividendsOnNetLossPerShareCalculation
2000000.0
fbio Effect Of Series Preferred Dividends On Net Loss Per Share Calculation
EffectOfSeriesPreferredDividendsOnNetLossPerShareCalculation
6000000.0
CY2023Q3 fbio Effect Of Partner Company Deemed Dividends On Net Loss Per Share Calculation
EffectOfPartnerCompanyDeemedDividendsOnNetLossPerShareCalculation
100000
fbio Effect Of Partner Company Deemed Dividends On Net Loss Per Share Calculation
EffectOfPartnerCompanyDeemedDividendsOnNetLossPerShareCalculation
400000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16852673
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1732987
CY2024Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
2000000.0
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6573000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4377000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16429000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13325000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
18896
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
20.55
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P1Y9M3D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
540000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.68
fbio Share Based Compensation Arrangement Options Granted Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementOptionsGrantedWeightedAverageRemainingContractualTerm
P6Y5M12D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
558896
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
2.32
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y3M7D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
18896
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
20.55
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P1Y3D
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5787289
CY2023Q4 fbio Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
1.88
CY2023Q4 fbio Class Of Warrant Or Right Weighted Average Intrinsic Value
ClassOfWarrantOrRightWeightedAverageIntrinsicValue
7794450
CY2023 fbio Class Of Warrant Or Right Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightWeightedAverageRemainingContractualLife
P4Y10M28D
fbio Class Of Warrant Or Right Number Of Shares Granted
ClassOfWarrantOrRightNumberOfSharesGranted
8729746
fbio Class Of Warrant Or Right Granted Weighted Average Exercise Price
ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice
2.35
fbio Class Of Warrant Or Right Number Of Shares Exercised
ClassOfWarrantOrRightNumberOfSharesExercised
-17500
fbio Class Of Warrant Or Right Expired Weighted Average Exercise Price
ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice
1.70
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
14499535
CY2024Q3 fbio Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
2.16
fbio Class Of Warrant Or Right Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightWeightedAverageRemainingContractualLife
P4Y8M15D
fbio Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
14499535
fbio Class Of Warrant Or Right Exercisable Weighted Average Exercise Price
ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
2.16
fbio Class Of Warrant Or Right Exercisable Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualLife
P4Y8M15D
CY2024Q3 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
7400000
CY2022Q4 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
150000000.0
CY2022Q4 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
4900000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
762000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
687000
us-gaap Operating Lease Cost
OperatingLeaseCost
1997000
us-gaap Operating Lease Cost
OperatingLeaseCost
2656000
CY2024Q3 us-gaap Sublease Income
SubleaseIncome
530000
CY2023Q3 us-gaap Sublease Income
SubleaseIncome
526000
us-gaap Sublease Income
SubleaseIncome
1571000
us-gaap Sublease Income
SubleaseIncome
1560000
CY2024Q3 us-gaap Variable Lease Cost
VariableLeaseCost
238000
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
220000
us-gaap Variable Lease Cost
VariableLeaseCost
628000
us-gaap Variable Lease Cost
VariableLeaseCost
620000
CY2024Q3 us-gaap Lease Cost
LeaseCost
470000
CY2023Q3 us-gaap Lease Cost
LeaseCost
381000
us-gaap Lease Cost
LeaseCost
1054000
us-gaap Lease Cost
LeaseCost
1716000
fbio Lessee Lease Portfolio And Other Supplemental Lease Information
LesseeLeasePortfolioAndOtherSupplementalLeaseInformation
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating cash flows from operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,744)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,652)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets exchanged for new operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (923)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term – operating leases (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate – operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table>
us-gaap Operating Lease Payments
OperatingLeasePayments
2744000
us-gaap Operating Lease Payments
OperatingLeasePayments
2652000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
923000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y10M24D
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y2M12D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.061
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.063
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
926000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3541000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3272000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2923000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2966000
CY2024Q3 fbio Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
8125000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
21753000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3947000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
17806000
fbio Annual Management Services Agreement Fee Income
AnnualManagementServicesAgreementFeeIncome
4000000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2024Q3 us-gaap Revenues
Revenues
14629000
CY2024Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5285000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9446000
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
21993000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4530000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
69000
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-26694000
us-gaap Revenues
Revenues
42555000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
18642000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46941000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
60867000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
2649000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8020000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-24000
us-gaap Profit Loss
ProfitLoss
-94540000
CY2023Q3 us-gaap Revenues
Revenues
34752000
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6429000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20348000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
21733000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3175000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
141000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-10724000
us-gaap Revenues
Revenues
64567000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
20645000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
91995000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
71512000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
3143000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2300000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
142000
us-gaap Profit Loss
ProfitLoss
-125170000
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
17844000
CY2024Q3 fbio Tangible Assets Net
TangibleAssetsNet
109241000
CY2024Q3 us-gaap Assets
Assets
127085000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
20287000
CY2023Q4 fbio Tangible Assets Net
TangibleAssetsNet
147239000
CY2023Q4 us-gaap Assets
Assets
167526000
CY2024Q3 us-gaap Revenues
Revenues
14629000
CY2023Q3 us-gaap Revenues
Revenues
34752000
us-gaap Revenues
Revenues
42555000
us-gaap Revenues
Revenues
64567000
fbio Minimum Ownership Interest In Subsidiaries For Consolidated Income Tax Return
MinimumOwnershipInterestInSubsidiariesForConsolidatedIncomeTaxReturn
0.80
fbio Minimum Ownership Interest In Subsidiaries For Consolidated Income Tax Return
MinimumOwnershipInterestInSubsidiariesForConsolidatedIncomeTaxReturn
0.80
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2024Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-24000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-015740-index-headers.html Edgar Link pending
0001558370-24-015740-index.html Edgar Link pending
0001558370-24-015740.txt Edgar Link pending
0001558370-24-015740-xbrl.zip Edgar Link pending
fbio-20240930.xsd Edgar Link pending
fbio-20240930x10q.htm Edgar Link pending
fbio-20240930xex10d4.htm Edgar Link pending
fbio-20240930xex10d5.htm Edgar Link pending
fbio-20240930xex31d1.htm Edgar Link pending
fbio-20240930xex31d2.htm Edgar Link pending
fbio-20240930xex32d1.htm Edgar Link pending
fbio-20240930xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
fbio-20240930_def.xml Edgar Link unprocessable
fbio-20240930_pre.xml Edgar Link unprocessable
fbio-20240930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
fbio-20240930x10q_htm.xml Edgar Link completed
fbio-20240930_cal.xml Edgar Link unprocessable